Evaluating Patients for Risk of Exocrine Pancreatic Insufficiency After ...
“The etiology of post-RYGB hyperoxaluria is not completely understood, but is believed to arise from enteric malabsorption due to reduced small intestine surface area available for nutrient absorption as well as a shortened gastrointestinal transit ...
MD Magazine - Wed, 08 Jul 2015 07:09

Alnylam to Host Second Annual Summer “RNAi Roundtable” Webcast Series
... ALN-PCSsc for the treatment of hypercholesterolemia, and ALN-GO1 for the treatment of Primary Hyperoxaluria Type 1. Speakers, dates, and times for these events will be posted on the Capella section of the company's website, www.alnylam.com/capella.
MarketWatch - Mon, 06 Jul 2015 12:52

Resurrection Plant Improves Sleep Quality in Cancer Patients
Renal calculi are the infrequent cause of renal failure even though primary hyperoxaluria, cystinuria, primary struvite stones, and infections with urolithiasis carry a great risk to it. Recurrent stone formation is also associated with risk of renal ...
AllAfrica.com - Wed, 22 Jul 2015 23:00

Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the ...
Hyperoxaluria is excessive urinary excretion of oxalate, a condition resulting from either hyperabsorption of dietary oxalate or the overproduction of oxalate in the body due to one of several known genetic defects. Hyperoxaluria, if left untreated ...
Business Wire (press release) - Wed, 18 Mar 2015 05:22

Dicerna Pharmaceuticals Receives Consensus Recommendation of "Strong Buy" from ...
In the rare disease field, the Company is developing a treatment, DCR-PH1, for the rare and serious inherited disorder Primary Hyperoxaluria 1 (PH1) by targeting the liver metabolic enzyme glycolate oxidase. The Company also has discovery and early ...
Dakota Financial News - Fri, 17 Jul 2015 05:33

Dicerna Pharmaceuticals Downgraded by Zacks (DRNA)
In the rare disease field, the Company is developing a treatment, DCR-PH1, for the rare and serious inherited disorder Primary Hyperoxaluria 1 (PH1) by targeting the liver metabolic enzyme glycolate oxidase. The Company also has discovery and early ...
Dakota Financial News - Tue, 14 Jul 2015 04:15

Zacks Downgrades Dicerna Pharmaceuticals to Hold (DRNA)
In the rare disease field, the Company is developing a treatment, DCR-PH1, for the rare and serious inherited disorder Primary Hyperoxaluria 1 (PH1) by targeting the liver metabolic enzyme glycolate oxidase. The Company also has discovery and early ...
WKRB News - Wed, 15 Jul 2015 10:26

Analysts Give $31.33 Average Price Target to Dicerna Pharmaceuticals (NASDAQ:DRNA)
In the rare disease field, the Company is developing a treatment, DCR-PH1, for the rare and serious inherited disorder Primary Hyperoxaluria 1 (PH1) by targeting the liver metabolic enzyme glycolate oxidase. The Company also has discovery and early ...
WKRB News - Mon, 20 Jul 2015 10:15


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014